Evidence map›Paper›PMID 30820708›Full record

ReviewDigestive diseases and sciences2019

Diagnosis and Treatment Patterns in Celiac Disease.

Allie B Cichewicz, Elizabeth S Mearns, Aliki Taylor, Talia Boulanger, Michele Gerber, Daniel A Leffler, Jennifer Drahos, David S Sanders, Kelly J Thomas Craig, Benjamin Lebwohl

Abstract readReview
PubMed Publisher
In one paragraph

Review in Digestive diseases and sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Recent advances in the diagnosis of celiac disease.World journal of gastroenterology · 2025
    Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Celiac Disease: A Review from Genetic to Treatment.Iranian biomedical journal · 2024
    Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Observational
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Allie B CichewiczIBM Watson Health, 75 Binney Street, Cambridge, MA, 02142, USA.
Elizabeth S MearnsIBM Watson Health, 75 Binney Street, Cambridge, MA, 02142, USA. elizabethmearns@gmail.com.
Aliki TaylorTakeda Development Centre Europe, 61 Aldwych, London, WC2B 4AE, UK.
Talia BoulangerIBM Watson Health, 75 Binney Street, Cambridge, MA, 02142, USA.
Michele GerberTakeda Pharmaceuticals International Co, 35 Landsdowne Street, Cambridge, MA, 02139, USA.
Daniel A LefflerTakeda Pharmaceuticals International Co, 35 Landsdowne Street, Cambridge, MA, 02139, USA.
Jennifer DrahosTakeda Pharmaceuticals International Co, 35 Landsdowne Street, Cambridge, MA, 02139, USA.
David S SandersRoyal Hallamshire Hospital and University of Sheffield, Glossop Road, Sheffield, S10 2FJ, UK.
Kelly J Thomas CraigIBM Watson Health, 75 Binney Street, Cambridge, MA, 02142, USA.
Benjamin LebwohlDepartment of Medicine, Celiac Disease Centre, Columbia University Medical Center, 180 Fort Washington Avenue, Suite 936, New York, NY, 10032, USA.
IBM (United States) · USTakeda (United States) · USColumbia University Irving Medical Center · USTakeda (United Kingdom) · GBUniversity of Sheffield · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Celiac disease (CD) is an immune-mediated gastrointestinal (GI) disorder driven by innate and adaptive immune responses to gluten. Presentation of CD has changed over time, with non-GI symptoms, such as anemia and osteoporosis, presenting more commonly. With improved screening and diagnostic methods, the reported prevalence of CD has increased globally, and there is considerable global variation in diagnostic and treatment practices. The objective of this study was to describe the current state of CD diagnosis and treatment patterns. A targeted review of literature from MEDLINE, Embase, the Cochrane Library, and screening of relevant conference abstracts was performed. The generally recommended diagnostic approach is GI endoscopy with small bowel biopsy; however, in selected patients, biopsy may be avoided and diagnosis based on positive serology and clinical symptoms. Diagnosis often is delayed; the average diagnostic delay after symptom onset is highly variable and can last up to 12 years. Barriers to accurate and timely diagnosis include atypical presentation, lack of physician awareness about current diagnostic criteria, misdiagnosis, and limited access to specialists. Currently, strict adherence to a gluten-free diet (GFD) is the only recommended treatment, which is not successful in all patients. Only one-third of patients are monitored regularly following diagnosis. Unmet needs for CD include improvements in the accuracy and timeliness of diagnosis, and the development of treatments for both refractory CD and GFD nonresponsive CD. Further research should investigate the impact of education about gluten-free eating and the availability of gluten-free foods support adherence and improve outcomes in patients with CD.

Indexed as

Diet, Gluten-FreeBiopsyCeliac DiseaseDelayed DiagnosisEndoscopy, GastrointestinalHumansAdherenceCeliac diseaseDiagnosisGluten-free dietReviewTreatment patterns

Identifiers

PMID30820708
OpenAlexW2920134694

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.